CB1 blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans

Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008

(2011) Zobair M. Younossi et al.   Clinical Gastroenterology and Hepatology

Liver Fat in the Pathogenesis of Insulin Resistance and Type 2 Diabetes

(2010) Hannele Yki-Järvinen   DIGESTIVE DISEASES

Nonalcoholic Fatty Liver Disease: A Review and Update

(2010) Jeffrey R. Lewis et al.   DIGESTIVE DISEASES AND SCIENCES

Splanchnic Balance of Free Fatty Acids, Endocannabinoids, and Lipids in Subjects With Nonalcoholic Fatty Liver Disease

(2010) Jukka Westerbacka et al.   GASTROENTEROLOGY

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

(2010) Eric J Topol et al.   LANCET

Dietary Fat and Carbohydrates Differentially Alter Insulin Sensitivity During Caloric Restriction

(2009) Erik Kirk et al.   GASTROENTEROLOGY

Diet and Exercise Interventions Reduce Intrahepatic Fat Content and Improve Insulin Sensitivity in Obese Older Adults

(2009) Krupa Shah et al.   Obesity

Effect of Rimonabant on the High-Triglyceride/ Low–HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat

(2008) Jean-Pierre Després et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease

(2008) K Kantartzis et al.   GUT

Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice

(2008) Douglas Osei-Hyiaman et al.   JOURNAL OF CLINICAL INVESTIGATION

Daily Cannabis Use: A Novel Risk Factor of Steatosis Severity in Patients With Chronic Hepatitis C

(2007) Christophe Hézode et al.   GASTROENTEROLOGY